Navigation Links
Intellect Neurosciences, Inc. Issues Letter to Shareholders From Its Chairman and CEO
Date:11/21/2008

er major companies.

Based on our transforming scientific discoveries and sound business model, Intellect is on track to become a major player in the discovery and development of drugs to treat AD, a devastating disease that is rapidly growing in prevalence and for which there are currently no efficacious disease-modifying treatments. We have made excellent progress towards achieving our goal for our company even in the face of a truly daunting financial market.

Financially, we continue to vigorously pursue various options to provide the funding necessary to fully realize the aforementioned strategy. We thank you for your patience and understanding as we go through this process.

As we move forward to realize the potential of our discoveries, we are grateful for the support and confidence of all of our shareholders. Be assured that we are steadfast in the pursuit of our goal to build a company that makes significant contributions to the public health and that brings outstanding financial rewards to its investors.

Thank you for your continued interest and support of Intellect Neurosciences, as we work to develop new drugs aimed at slowing or preventing Alzheimer's disease.

Sincerely,

Daniel Chain, Ph.D.

About Intellect Neurosciences, Inc.

Intellect Neurosciences, Inc. is a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of AD and other disorders. The Company has a broad proprietary immunotherapy platform for both passive and active immunization against AD. Also, Intellect has completed Phase I clinical trials for OXIGON(R), which has the potential to be used as a treatment for AD and other serious disorders.

For additional information, please visit
'/>"/>

SOURCE Intellect Neurosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
4. Nastech Assigns Intellectual Property Related to the Development of RNA-Based Therapeutics to its Subsidiary, MDRNA, Inc.
5. ActivBiotics Completes Sale of Fixed Assets; Expands Due Diligence Initiative for the Sale of Intellectual Property, Including Drug Product Candidates
6. Amarin Secures Global Intellectual Property Rights for Lipid Programs
7. ActivBiotics Intellectual Property Assets, Including Drug Product Candidates, Sold for $3.5 Million
8. Intradigm Licenses Key Next Generation RNA Interference (RNAi) Intellectual Property From University of Massachusetts Medical School
9. Intellect Neurosciences, Inc. Receives Notice of Allowance and Completes Grant Requirements for Pivotal European Patent Related to Passive Immunization of Alzheimers Disease
10. Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate
11. IC Sciences Announces Launch of ICS Advisory Services Intellectual Property Platforms Available Through ICSciences Alliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... SPRING, Md. , Dec. 24, 2014 /PRNewswire/ ... announced today that Medtronic, Inc. (NYSE: ... to the U.S. Food and Drug Administration (FDA) ... II implantable drug infusion system (including a newly ... ® (treprostinil) Injection delivered intravenously to patients ...
(Date:12/24/2014)... 24, 2014  Vermillion, Inc. (Nasdaq:   VRML), ... announced today that the Company closed its previously ... Management, Jack W. Schuler , Birchview Fund ... $10.5 million, before offering expenses.  The proceeds will ... purposes. Under the terms of the ...
(Date:12/24/2014)... “Preparative & Process Chromatography Market by ... Solvents, Buffers, Valves, Guages, Seals), Accessories, Services, End ... to 2019” provides a detailed overview of the ... and strategies impacting the preparative and process chromatography ... the revenue and share analysis. , Full ...
(Date:12/24/2014)... 23, 2014 Earlier this year in ... Sherley, director of the Adult Stem Cell Technology Center, ... overlooked and under appreciated unique property of adult tissue ... Stem Cells: Misunderstood in the Past, Important for the ... participants. He gave the address at the 4th ...
Breaking Biology Technology:United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4
... , COLUMBIA, Md., Aug. 19 Martek Biosciences Corporation ... results of its third quarter of fiscal 2009 on September 2, 2009, ... 4:45 p.m. ET Martek will conduct a conference call to discuss these ... live via webcast by visiting Martek,s web site at http://investors.martek.c ...
... , , , , ... WASHINGTON, Aug.19 A scholarly analysis of the keystone of indirect ... science fell far short of acceptable scientific standards. Professor John Mathews and ... exhaustive analysis of Searchinger et al. which revealed that the ...
... LAFAYETTE, Ind. - Researchers are adapting the same methods ... beams for a new class of "nanolithography" required to ... light to create the fine features in computer chips ... image of a mask onto a light-sensitive material, then ...
Cached Biology Technology:Analysis of Biofuels Indirect Land Use Effects Finds the Science Lacking: 'Too Diffuse and Subject To Too Many Arbitrary Assumptions To Be Useful for Rule-making.' 2Analysis of Biofuels Indirect Land Use Effects Finds the Science Lacking: 'Too Diffuse and Subject To Too Many Arbitrary Assumptions To Be Useful for Rule-making.' 3Nuclear fusion research key to advancing computer chips 2Nuclear fusion research key to advancing computer chips 3
(Date:12/22/2014)... 22, 2014 Research and Markets ... addition of the "The Global Watermarking ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... overview of the global digital media watermarking ... and monitor piracy by securely and invisibly ...
(Date:12/19/2014)... , Dec. 18, 2014  23andMe, Inc., the leading ... study that pinpoints fine-scale differences in genetic ancestry of ... . Since immigrants first arrived more than ... has served as a meeting place for ... history and the ongoing mixing of peoples with African, ...
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM ... Clinical Practices (GCP) audit to confirm its adherence ... regulations. This accomplishment enables HITLAB to conduct regulated ... the highest principles for patient safety and research ... global healthcare access, quality, and delivery with innovative ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
... Upton, NY -- An international team of researchers from ... the genomes of two important laboratory strains of E. ... other to produce proteins for basic research or practical applications. ... open a window to a deeper understanding of classical research ...
... 20, 2009Doctor of the Heart: My Life in Medicine ... best-selling author, and popular television commentator. Published by Mary ... account of his long and extraordinary career ( www.liebertpub.com/heart ... often referred to as "America,s Doctor." "Through his works ...
... disease for which there,s a proven cure, but nobody makes ... many around the world face every day and one Rice ... Internet. The Cure for Needy Project ( http://www.cureforneedy.org ... optimize small-molecule medications for orphaned diseases those for which ...
Cached Biology News:Genomes of 2 popular research strains of E. coli sequenced 2Genomes of 2 popular research strains of E. coli sequenced 3Just published: 'Doctor of the Heart: My Life in Medicine,' by Isadore Rosenfeld, M.D. 2Rice opens 'Cure for Needy' on the Web 2Rice opens 'Cure for Needy' on the Web 3
Fluorescein-CSCSSLMDKECVYFCHLDIIW (Disulfide bridge: 1-15 and 3-11)...
... for isolation and affinity purification of ... peptides. Hydrophobic, monodisperse magnetic particles (2.8 ... groups, further surface activation is not ... with optimal orientation for affinity purification ...
VMAT 2 (N-19)...
Neuropilin-2 Purified Anti-Rat clone 54, Isotype Mouse IgG 1 , 150 µg Consult technical datasheet for details....
Biology Products: